今年已有九只基金翻倍 创新药主题基金强势领涨

Group 1 - The innovative drug sector has seen significant performance this year, with multiple funds achieving net value doubling, and the top performer nearing a 140% return, leading to a suspension of new subscriptions [1][2] - As of July 28, the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund (QDII), reported a return of 139.12%, while several other funds also exceeded 100% returns [2][3] - The strong performance has attracted substantial capital inflow, with notable net subscriptions for various innovative drug ETFs, indicating high investor interest [4][6] Group 2 - The innovative drug sector is characterized by high volatility, with expectations of continued favorable factors for quality company valuations, despite recent significant price increases [1][6] - Upcoming clinical data and academic conferences, such as the European Society of Cardiology Congress and the European Society for Medical Oncology Congress, are anticipated to catalyze further developments in the sector [6] - The internationalization of China's innovative drug industry is accelerating, with increasing collaboration with multinational companies, enhancing investor confidence in the sector's growth potential [7]